Jrg H W Distler

List of Publications by Year in Descending Order

208 papers	18,592 citations	65 h-index	134 g-index
225 ext. papers	23,688 ext. citations	5.9 avg, IF	6.9 L-index

#	Paper	IF	Citations
208	LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis.. *Clinical and Translational Medicine*, **2022**, 12, e711	5.7	1
207	The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.. *Therapeutic Advances in Musculoskeletal Disease*, **2022**, 14, 1759720X221074457	3.8	1
206	PatientÖs Perception of Digital Symptom Assessment Technologies in Rheumatology: Results From a Multicentre Study.. *Frontiers in Public Health*, **2022**, 10, 844669	6	0
205	68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. *Lancet Rheumatology, The*, **2021**, 3, e185-e194	14.2	9
204	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. *Lancet Rheumatology, The*, **2021**, 3, e175-e184	14.2	3
203	Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. *Blood*, **2021**, 137, 2403-2416	2.2	5
202	Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial. *Arthritis Research and Therapy*, **2021**, 23, 112	5.7	7
201	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. *Biomedicines*, **2021**, 9,	4.8	1
200	Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 681061	5.7	2
199	Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease ÖAuthorsÖ reply. *Lancet Rheumatology, The*, **2021**, 3, e475-e477	14.2	
198	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. *Arthritis Research and Therapy*, **2021**, 23, 204	5.7	1
197	Response to: Ön search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?Ö by Manetti and Matucci-Cerinic. *Annals of the Rheumatic Diseases*, **2021**, 80, e150	2.4	0
196	Reply. *Arthritis and Rheumatology*, **2021**, 73, 179-180	9.5	1
195	Cellular and molecular mechanisms in fibrosis. *Experimental Dermatology*, **2021**, 30, 121-131	4	8
194	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. *Scientific Reports*, **2021**, 11, 1	4.9	2785
193	Mouse Models of Skin Fibrosis. *Methods in Molecular Biology*, **2021**, 2299, 371-383	1.4	2
192	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 96-106	35.1	38

191	Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma. *Annals of the Rheumatic Diseases*, **2021**, 80, 920-929	2.4	7
190	Platelet phagocytosis via PSGL1 and accumulation of microparticles in systemic sclerosis. *Arthritis and Rheumatology*, **2021**,	9.5	2
189	TGF promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy. *Nature Communications*, **2021**, 12, 4404	17.4	8
188	Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation. *Journal of Experimental Medicine*, **2021**, 218,	16.6	1
187	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score. *Arthritis and Rheumatology*, **2021**,	9.5	5
186	The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 131, 134-141	2.2	
185	The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease. *Clinical and Experimental Rheumatology*, **2021**, 39, 134-141	2.2	1
184	PGC-1 regulates autophagy to promote fibroblast activation and tissue fibrosis. *Annals of the Rheumatic Diseases*, **2020**, 79, 1227-1233	2.4	6
183	Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis. *Arthritis and Rheumatology*, **2020**, 72, 1385-1395	9.5	9
182	Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. *PLoS ONE*, **2020**, 15, e0229445	3.7	7
181	The 7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders. *Journal of Investigative Dermatology*, **2020**, 140, 2371-2379	4.3	2
180	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. *British Journal of Pharmacology*, **2020**, 177, 4296-4309	8.6	12
179	Predictors of progression in systemic sclerosis patients with interstitial lung disease. *European Respiratory Journal*, **2020**, 55,	13.6	52
178	microRNA-145 mediates xylosyltransferase-I induction in myofibroblasts via suppression of transcription factor KLF4. *Biochemical and Biophysical Research Communications*, **2020**, 523, 1001-1006	3.4	3
177	Therapeutic molecular targets of SSc-ILD.. *Journal of Scleroderma and Related Disorders*, **2020**, 5, 17-30	2.3	6
176	TGF-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. *Journal of Clinical Investigation*, **2020**, 130, 2347-2363	15.9	24
175	Long noncoding RNA H19X is a key mediator of TGF-driven fibrosis. *Journal of Clinical Investigation*, **2020**, 130, 4888-4905	15.9	19
174	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. *Rheumatology*, **2020**, 59, 1684-1694	3.9	9

173	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. *Science Translational Medicine*, **2020**, 12,	17.5	14
172	Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. *Annals of the Rheumatic Diseases*, **2020**, 79, 1485-1491	2.4	45
171	cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. *Rheumatology*, **2020**, 59, 3939-3951	3.9	3
170	Response to: Correspondence on Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis by Jeny. *Annals of the Rheumatic Diseases*, **2020**,	2.4	4
169	Comment on: Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria by Greco. *Annals of the Rheumatic Diseases*, **2020**, 79, e85	2.4	5
168	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. *Arthritis and Rheumatology*, **2020**, 72, 137-149	9.5	42
167	Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. *Annals of the Rheumatic Diseases*, **2020**,	2.4	13
166	PU.1 controls fibroblast polarization and tissue fibrosis. *Nature*, **2019**, 566, 344-349	50.4	67
165	Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts. *Journal of Investigative Dermatology*, **2019**, 139, 439-447	4.3	13
164	Acyltransferase skinny hedgehog regulates TGF dependent fibroblast activation in SSc. *Annals of the Rheumatic Diseases*, **2019**, 78, 1269-1273	2.4	12
163	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.. *Journal of Scleroderma and Related Disorders*, **2019**, 4, 212-218	2.3	19
162	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. *Annals of the Rheumatic Diseases*, **2019**, 78, 979-987	2.4	95
161	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. *Clinical Rheumatology*, **2019**, 38, 2673-2681	3.9	25
160	Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. *Journal of Controlled Release*, **2019**, 310, 198-208	11.7	15
159	Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA-125b in Systemic Sclerosis. *Arthritis and Rheumatology*, **2019**, 71, 2068-2080	9.5	8
158	Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. *European Respiratory Journal*, **2019**, 54,	13.6	90
157	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. *Nature Communications*, **2019**, 10, 4955	17.4	46
156	Shared and distinct mechanisms of fibrosis. *Nature Reviews Rheumatology*, **2019**, 15, 705-730	8.1	134

155	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. *Annals of the Rheumatic Diseases*, **2019**, 78, 1681-1685	2.4	3
154	Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. *Annals of the Rheumatic Diseases*, **2019**, 78, 1686-1692	2.4	15
153	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. *Journal of Clinical Medicine*, **2019**, 8,	5.1	48
152	Targeting TGF-signaling for the treatment of fibrosis. *Matrix Biology*, **2018**, 68-69, 8-27	11.4	116
151	Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2018**, 77, 744-751	2.4	27
150	Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis. *Journal of Immunology*, **2018**, 200, 1249-1254	5.3	54
149	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. *Annals of the Rheumatic Diseases*, **2018**, 77, 459	2.4	27
148	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. *Annals of the Rheumatic Diseases*, **2018**, 77, 563-570	2.4	31
147	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. *Rheumatology*, **2018**, 57, 370-381	3.9	36
146	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2018**, 77, 626-628	2.4	10
145	The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2018**, 77, 150-158	2.4	32
144	Innate lymphoid cells and fibrotic regulation. *Immunology Letters*, **2018**, 195, 38-44	4.1	11
143	Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus. *Frontiers in Immunology*, **2018**, 9, 989	8.4	8
142	The tyrosine phosphatase SHP2 controls TGFnduced STAT3 signaling to regulate fibroblast activation and fibrosis. *Nature Communications*, **2018**, 9, 3259	17.4	60
141	NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover. *Journal of Bone and Mineral Research*, **2018**, 33, 2035-2047	6.3	13
140	Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling. *Annals of the Rheumatic Diseases*, **2017**, 76, 773-778	2.4	15
139	Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. *Annals of the Rheumatic Diseases*, **2017**, 76, 1133-1141	2.4	40
138	The transcription factor GLI2 as a downstream mediator of transforming growth factor-nduced fibroblast activation in SSc. *Annals of the Rheumatic Diseases*, **2017**, 76, 756-764	2.4	28

137	Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. *Annals of the Rheumatic Diseases*, **2017**, 76, 244-251	2.4	22
136	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). *Annals of the Rheumatic Diseases*, **2017**, 76, 1207-1218	2.4	71
135	JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. *Annals of the Rheumatic Diseases*, **2017**, 76, 1467-1475	2.4	28
134	Epigenetic factors as drivers of fibrosis in systemic sclerosis. *Epigenomics*, **2017**, 9, 463-477	4.4	24
133	Update of EULAR recommendations for the treatment of systemic sclerosis. *Annals of the Rheumatic Diseases*, **2017**, 76, 1327-1339	2.4	497
132	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. *Nature Communications*, **2017**, 8, 1130	17.4	155
131	Mapping and predicting mortality from systemic sclerosis. *Annals of the Rheumatic Diseases*, **2017**, 76, 1897-1905	2.4	230
130	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. *Annals of the Rheumatic Diseases*, **2017**, 76, 1941-1948	2.4	96
129	Tie2 as a novel key factor of microangiopathy in systemic sclerosis. *Arthritis Research and Therapy*, **2017**, 19, 105	5.7	19
128	Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. *Experimental Dermatology*, **2017**, 26, 73-81	4	26
127	Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis. *Arthritis and Rheumatology*, **2017**, 69, 257-267	9.5	46
126	Overview of Animal Models **2017**, 281-293		
125	Activating transcription factor 3 regulates canonical TGF□signalling in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2016**, 75, 586-92	2.4	24
124	Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. *Annals of the Rheumatic Diseases*, **2016**, 75, 623-6	2.4	59
123	Inactivation of autophagy ameliorates glucocorticoid-induced and ovariectomy-induced bone loss. *Annals of the Rheumatic Diseases*, **2016**, 75, 1203-10	2.4	71
122	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. *Annals of the Rheumatic Diseases*, **2016**, 75, 883-90	2.4	120
121	Sirt1 regulates canonical TGF-□signalling to control fibroblast activation and tissue fibrosis. *Annals of the Rheumatic Diseases*, **2016**, 75, 226-33	2.4	94
120	Evidence of innate lymphoid cell redundancy in humans. *Nature Immunology*, **2016**, 17, 1291-1299	19.1	196

119	Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. *Arthritis and Rheumatology*, **2016**, 68, 2338-44	9.5	35
118	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. *Annals of the Rheumatic Diseases*, **2016**, 75, 303-10	2.4	37
117	Tribbles homologue 3 stimulates canonical TGF- signalling to regulate fibroblast activation and tissue fibrosis. *Annals of the Rheumatic Diseases*, **2016**, 75, 609-16	2.4	24
116	Canonical Wnt signaling in systemic sclerosis. *Laboratory Investigation*, **2016**, 96, 151-5	5.9	36
115	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
114	Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. *Annals of the Rheumatic Diseases*, **2016**, 75, 1521-6	2.4	29
113	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. *Annals of the Rheumatic Diseases*, **2016**, 75, 1285-92	2.4	45
112	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. *PLoS ONE*, **2016**, 11, e0163894	3.7	99
111	Emerging strategies for treatment of systemic sclerosis. *Journal of Scleroderma and Related Disorders*, **2016**, 1, 186-193	2.3	36
110	Updates on animal models of systemic sclerosis. *Journal of Scleroderma and Related Disorders*, **2016**, 1, 266-276	2.3	14
109	Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. *Annals of the Rheumatic Diseases*, **2016**, 75, 2037-2044	2.4	16
108	Tocilizumab for systemic sclerosis: implications for future trials. *Lancet, The*, **2016**, 387, 2580-2581	40	11
107	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. *Rheumatology*, **2015**, 54, 2273-82	3.9	14
106	From pathogenesis to therapy--Perspective on treatment strategies in fibrotic diseases. *Pharmacological Research*, **2015**, 100, 93-100	10.2	15
105	Cardiomyopathy in murine models of systemic sclerosis. *Arthritis and Rheumatology*, **2015**, 67, 508-16	9.5	29
104	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. *Annals of the Rheumatic Diseases*, **2015**, 74, 1621-5	2.4	49
103	Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. *Annals of the Rheumatic Diseases*, **2015**, 74, 1317-24	2.4	24
102	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. *Annals of the Rheumatic Diseases*, **2015**, 74, 1188-94	2.4	267

101	S100A4 amplifies TGF-induced fibroblast activation in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2015**, 74, 1748-55	2.4	34
100	Vitamin D receptor regulates TGF-signalling in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2015**, 74, e20	2.4	87
99	Inhibition of casein kinase II reduces TGFinduced fibroblast activation and ameliorates experimental fibrosis. *Annals of the Rheumatic Diseases*, **2015**, 74, 936-43	2.4	30
98	Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF signalling. *Annals of the Rheumatic Diseases*, **2015**, 74, 1408-16	2.4	78
97	Orphan nuclear receptor NR4A1 regulates transforming growth factor-signaling and fibrosis. *Nature Medicine*, **2015**, 21, 150-8	50.5	195
96	Anti-Fibrotic Effect of Ajulemic Acid in Bleomycin-Induced Lung Fibrosis. *FASEB Journal*, **2015**, 29, LB744	0.9	
95	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. *Clinical and Experimental Rheumatology*, **2015**, 33, S31-5	2.2	4
94	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. *Clinical and Experimental Rheumatology*, **2015**, 33, S75-9	2.2	13
93	Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. *Annals of the Rheumatic Diseases*, **2014**, 73, 1264-8	2.4	29
92	The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2014**, 73, 1232-9	2.4	136
91	Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. *Annals of the Rheumatic Diseases*, **2014**, 73, 624-7	2.4	22
90	Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. *American Journal of Human Genetics*, **2014**, 94, 47-61	11	151
89	A3.19 mIR-193B induces UPA in SSC and contributes to the proliferative vasculopathy via uPAR independent pathways. *Annals of the Rheumatic Diseases*, **2014**, 73, A49.2-A49	2.4	
88	Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. *Annals of the Rheumatic Diseases*, **2014**, 73, 1880-7	2.4	60
87	The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor and contributes to the development of experimental dermal fibrosis. *Arthritis and Rheumatology*, **2014**, 66, 3140-50	9.5	12
86	Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?. *Current Opinion in Pharmacology*, **2013**, 13, 455-62	5.1	12
85	Activation of pregnane X receptor inhibits experimental dermal fibrosis. *Annals of the Rheumatic Diseases*, **2013**, 72, 621-5	2.4	19
84	Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. *Archives of Dermatological Research*, **2013**, 305, 1-8	3.3	23

83	The Fra-2 transgenic mouse model of systemic sclerosis. *Vascular Pharmacology*, **2013**, 58, 194-201	5.9	44
82	Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. *Annals of the Rheumatic Diseases*, **2013**, 72, 614-20	2.4	78
81	Morphogen pathways in systemic sclerosis. *Current Rheumatology Reports*, **2013**, 15, 299	4.9	19
80	Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2013**, 1832, 897-904	6.9	81
79	Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. *Annals of the Rheumatic Diseases*, **2013**, 72, 1575-80	2.4	57
78	Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. *Annals of the Rheumatic Diseases*, **2013**, 72, 1255-8	2.4	92
77	Canonical Wnt signalling as a key regulator of fibrogenesis - implications for targeted therapies?. *Experimental Dermatology*, **2013**, 22, 710-3	4	39
76	Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. *Annals of the Rheumatic Diseases*, **2013**, 72, 2039-46	2.4	17
75	New insight on the Xq28 association with systemic sclerosis. *Annals of the Rheumatic Diseases*, **2013** , 72, 2032-8	2.4	48
74	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. *Annals of the Rheumatic Diseases*, **2013**, 72, 1089-98	2.4	30
73	Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover. *Journal of Bone and Mineral Research*, **2013**, 28, 936-47	6.3	10
72	Autophagy: a key pathway of TNF-induced inflammatory bone loss. *Autophagy*, **2013**, 9, 1253-5	10.2	45
71	A8.3 Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model. *Annals of the Rheumatic Diseases*, **2013**, 72, A58.1-A58	2.4	
70	The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. *PLoS ONE*, **2013**, 8, e54419	3.7	32
69	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. *Blood*, **2012**, 120, 2909-17	2.2	49
68	Inhibition of sumoylation prevents experimental fibrosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 1904-8	2.4	25
67	Influence of the IL6 gene in susceptibility to systemic sclerosis. *Journal of Rheumatology*, **2012**, 39, 2294-302	4.1	26
66	Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 1382-7	2.4	80

65	JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor □n systemic sclerosis. *Arthritis and Rheumatism*, **2012**, 64, 3006-15		89
64	Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. *American Journal of Pathology*, **2012**, 181, 1672-80	5.8	25
63	Activation of canonical Wnt signalling is required for TGF-□mediated fibrosis. *Nature Communications*, **2012**, 3, 735	17.4	501
62	WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. *Journal of Bone and Mineral Research*, **2012**, 27, 575-85	6.3	83
61	Inhibition of activator protein 1 signaling abrogates transforming growth factor □mediated activation of fibroblasts and prevents experimental fibrosis. *Arthritis and Rheumatism*, **2012**, 64, 1642-52		65
60	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. *Arthritis and Rheumatism*, **2012**, 64, 2724-33		110
59	□catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 761-7	2.4	147
58	The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 1081-7	2.4	33
57	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. *Human Molecular Genetics*, **2012**, 21, 926-33	5.6	70
56	Innovative antifibrotic therapies in systemic sclerosis. *Current Opinion in Rheumatology*, **2012**, 24, 274-80	5.3	43
55	Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 1545-51	2.4	69
54	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 737-45	2.4	46
53	Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 785-9	2.4	63
52	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 1019-26	2.4	65
51	Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. *Annals of the Rheumatic Diseases*, **2012**, 71, 1895-9	2.4	27
50	Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. *Annals of the Rheumatic Diseases*, **2012**, 71, 2051-4	2.4	22
49	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. *Human Molecular Genetics*, **2012**, 21, 2825-35	5.6	79
48	Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 756-62	5.6	38

47	Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. *Current Rheumatology Reports*, **2011**, 13, 21-7	4.9	32
46	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. *Arthritis and Rheumatism*, **2011**, 63, 800-9		63
45	Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. *Arthritis and Rheumatism*, **2011**, 63, 1396-404		92
44	Induction of apoptosis in circulating angiogenic cells by microparticles. *Arthritis and Rheumatism*, **2011**, 63, 2067-77		34
43	Inhibition of glycogen synthase kinase 3 induces dermal fibrosis by activation of the canonical Wnt pathway. *Annals of the Rheumatic Diseases*, **2011**, 70, 2191-8	2.4	82
42	Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2011**, 70, 1304-10	2.4	97
41	The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2011**, 70, 1320-6	2.4	45
40	Platelet-derived serotonin links vascular disease and tissue fibrosis. *Journal of Experimental Medicine*, **2011**, 208, 961-72	16.6	190
39	Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. *PLoS Genetics*, **2011**, 7, e1002091	6	176
38	Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. *Annals of the Rheumatic Diseases*, **2011**, 70, 1197-202	2.4	17
37	The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. *Arthritis and Rheumatism*, **2010**, 62, 280-90		83
36	Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. *Arthritis and Rheumatism*, **2010**, 62, 1513-22		16
35	MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. *Arthritis and Rheumatism*, **2010**, 62, 1733-43		409
34	Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. *Arthritis and Rheumatism*, **2010**, 62, 3467-76		51
33	Animal models of systemic sclerosis: prospects and limitations. *Arthritis and Rheumatism*, **2010**, 62, 2831-44		113
32	Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. *Circulation*, **2009**, 120, 2367-76	16.7	85
31	Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 4185-91	5.6	8
30	Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. *Arthritis and Rheumatism*, **2009**, 60, 219-24		162

29	The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. *Arthritis and Rheumatism*, **2009**, 60, 1129-36		91
28	Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. *Arthritis and Rheumatism*, **2009**, 60, 1519-29		87
27	Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. *Arthritis and Rheumatism*, **2009**, 60, 3168-79		31
26	Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. *Arthritis and Rheumatism*, **2009**, 60, 3663-75		13
25	Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. *Arthritis Research and Therapy*, **2009**, 11, 2205.7		73
24	The scientific basis for novel treatments of systemic sclerosis. *F1000 Medicine Reports*, **2009**, 1,		3
23	Novel treatment approaches to fibrosis in scleroderma. *Rheumatic Disease Clinics of North America*, **2008**, 34, 145-59; vii	2.4	7
22	Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. *FASEB Journal*, **2008**, 22, 2214-22	0.9	169
21	Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis. *Nature Clinical Practice Rheumatology*, **2008**, 4, 160-4		2
20	Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. *Arthritis and Rheumatism*, **2008**, 58, 1475-84		103
19	Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. *Arthritis and Rheumatism*, **2008**, 58, 2553-64		88
18	Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. *Arthritis and Rheumatism*, **2008**, 58, 2538-42		36
17	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. *Arthritis and Rheumatism*, **2008**, 58, 2845-53		77
16	Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. *Arthritis and Rheumatism*, **2007**, 56, 311-22		317
15	Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. *Arthritis and Rheumatism*, **2007**, 56, 2755-64		134
14	Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. *Arthritis and Rheumatism*, **2007**, 56, 3564-74		69
13	Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. *Arthritis and Rheumatism*, **2007**, 56, 4203-15		139
12	The role of membrane lipids in the induction of macrophage apoptosis by microparticles. *Apoptosis: an International Journal on Programmed Cell Death*, **2007**, 12, 363-74	5.4	52

11	Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?. *Annals of the Rheumatic Diseases*, **2007**, 66, 836	2.4	13
10	Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. *Arthritis and Rheumatism*, **2006**, 54, 214-25		81
9	Microparticles as mediators of cellular cross-talk in inflammatory disease. *Autoimmunity*, **2006**, 39, 683-90	3	131
8	Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*. *Experimental Dermatology*, **2005**, 14, 315-20	4	40
7	Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. *Arthritis and Rheumatism*, **2005**, 52, 856-64		103
6	Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. *Arthritis and Rheumatism*, **2005**, 52, 3337-48		179
5	The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 2892-7	11.5	336
4	Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. *Molecular Pharmacology*, **2004**, 65, 389-99	4.3	21
3	Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. *Arthritis and Rheumatism*, **2004**, 50, 10-23		83
2	Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. *Arthritis and Rheumatism*, **2004**, 50, 1468-76		133
1	Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. *Circulation Research*, **2004**, 95, 109-16	15.7	248